The Evaluation of Patients with Severe COVID-19 Pneumonia Who are Recieving Favipiravir Treatment

Autor: Servet ÖZTÜRK, Onur ÇOLAK, Semra KAVAS, Derya ÖZTÜRK ENGİN, Serap DİKTAŞ TAHTASAKAL, Dilek ERDOĞAN ARI, Öznur DEMİROLUK, Berna ÖZDEMİR, Büşra Meral ÇETİNKAYA, Merve KAÇAR EKER, İrem Asena DOĞAN, Haluk VAHABOĞLU, Canan AĞALAR
Jazyk: turečtina
Rok vydání: 2021
Předmět:
Zdroj: Mediterranean Journal of Infection, Microbes and Antimicrobials, Vol 10, Iss 1 (2021)
Druh dokumentu: article
ISSN: 2147-673X
DOI: 10.4274/mjima.galenos.2021.2020.22
Popis: Introduction: There is no known specific treatment for Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Our retrospective study evaluates the effectiveness of steroid treatment and the factors affecting treatment in patients with severe Coronavirus disease-2019 (COVID-19) pneumonia that received favipiravir treatment. Materials and Methods: This study included patients older than 18 years with severe COVID-19 pneumonia who received favipiravir treatment in a training and research hospital between March 1 and May 31, 2020. It retrospectively evaluated respiratory rate >30/min and/or severe respiratory distress and oxygen saturation
Databáze: Directory of Open Access Journals